Browse Studies — Arctuva

Phase 2

Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease control for participants with metastati…

Metastatic Invasive Breast CancerResistant Breast CancerER+, HER2-, Metastatic Breast Cancer

Estimated

~$10 – $6,250